Press Releases Archives | Page 16 of 119

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease

May 27, 2025 By BioInformant Team Leave a Comment

Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly approved Phase 1 clinical trial for Alzheimer’s disease. The A3D trial has received authorization from the European Medicines Agency (EMA).

A3D is sponsored and promoted by CHU Toulouse, in collaboration with the Clinical Investigation Center in Biotherapy (CIC-BT), and coordinated by Dr Julien Delrieu, Principal Investigator of the study.

San Antonio healthcare services organization launches first-in-the-world mobile leukapheresis center supporting cell and gene therapies

May 7, 2025 By BioInformant Team Leave a Comment

New BBG Advanced Therapies vehicle will help bring lifesaving treatments to a wider patient base

San Antonio, Texas, May 06, 2025 – BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, has unveiled the first vehicle of its kind in the world, a mobile leukapheresis center designed to perform leukapheresis collections of starting materials for cell and gene therapies.

[Read more…]

Pioneering the future of sports with iPS cells
FUNROOTS, I Peace, and Reju form a strategic alliance

May 7, 2025 By Cade Hildreth, Founder & President Leave a Comment

FUNROOTS Co., Ltd. (Tokyo, Japan), I Peace, Inc. (California, USA), and Reju Inc. (Tokyo, Japan) entered a strategic partnership to integrate cutting-edge iPS cell technology into the sports industry, aiming to deliver innovative health management solutions, enhance athletic performance, and accelerate injury recovery, leveraging advancements in regenerative medicine. [Read more…]

Curi Bio and Cook MyoSite Announce Strategic Partnership

May 1, 2025 By BioInformant Team Leave a Comment

Curi Bio and Cook MyoSite Announce Strategic Scientific Collaboration to Advance Translational Human Muscle Disease Models

SEATTLE & PITTSBURGH — Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based therapies, today announced a strategic partnership to develop advanced, predictive human engineered tissue models aimed at addressing muscle-related diseases and metabolic disorders, including obesity and diabetes. [Read more…]

RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing

April 30, 2025 By Cade Hildreth, Founder & President Leave a Comment

FREDERICK, MD., (April 29, 2025) —RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease. [Read more…]